https://www.selleckchem.com/pr....oducts/gsk650394.htm
Copyright © 2020 Story, Miller, Bradbury, Million, Duan, Taghian, Faissler, Fernau, Beecy and Gray-Edwards.Glioblastoma (GBM) is the most common and aggressive intracranial malignant brain tumor, and the abnormal expression of HDAC1 is closely correlated to the progression, recurrence and metastasis of GBM cells, making selective inhibition of HDAC1 a promising strategy for GBM treatments. Among all available selective HDAC1 inhibitors, the macrocyclic peptides have gained great attention due to their remarkable inhibitory selectivity
Like
Comment
Share
